scispace - formally typeset
M

Michael J. Baum

Researcher at Boston University

Publications -  370
Citations -  27670

Michael J. Baum is an academic researcher from Boston University. The author has contributed to research in topics: Breast cancer & Olfactory system. The author has an hindex of 68, co-authored 368 publications receiving 26574 citations. Previous affiliations of Michael J. Baum include University of Cambridge & Erasmus University Rotterdam.

Papers
More filters
Journal ArticleDOI

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 - 
TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal Article

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, +226 more
- 18 Sep 1998 - 
TL;DR: The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given.
Journal ArticleDOI

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

TL;DR: Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer and longer follow-up is required before a final benefit:risk assessment can be made.
Journal ArticleDOI

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

TL;DR: There was no convincing heterogeneity in the proportional recurrence reduction with respect to age, nodal status, tumor grade, or progesterone receptor status and no indication of an increase in nonbreast deaths with AIs in either cohort.
Journal ArticleDOI

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

TL;DR: Prophylactic use of tamoxifen is contraindicated in women at high risk of thromboembolic disease and the combined evidence indicates that mortality from non-breast-cancer causes is not increased by tamoxIFen.